Wang Qiuming, Wu Heming, Lan Yongquan, Zhang Jinhong, Wu Jingna, Zhang Yunuo, Li Liang, Liu Donghua, Zhang Jinfeng
Department of Medical Oncology, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou, People's Republic of China.
Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka Population, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou, People's Republic of China.
Int J Gen Med. 2021 Oct 29;14:7371-7380. doi: 10.2147/IJGM.S333858. eCollection 2021.
Although the burden of breast cancer remains especially high in rural China, data on the clinicopathological characteristics and prevalence of the breast cancer susceptibility gene 1/2 () mutations in patients with breast cancer remain limited. We investigated the clinicopathological characteristics, changing patterns, and prevalence of mutations in patients with breast cancer.
The clinicopathological characteristics of 3712 women with pathologically confirmed primary breast cancer treated at Meizhou People's Hospital between January 2005 and December 2018 were evaluated. The prevalence of mutations in 340 patients with breast cancer diagnosed between January 2017 and September 2018 was also evaluated.
The median age at diagnosis was 49±10.5 (range, 20-94) years. Positivity for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was observed in 59.0%, 52.5%, and 24.9% of patients, respectively. Time trend analysis revealed that an increasing trend was observed for age at diagnosis ( = 0.001), proportion of patients without a reproductive history ( < 0.001), postmenopausal patients ( = 0.001), invasive pathological cancer type ( = 0.008), ER-positive rate ( < 0.001), PR-positive rate ( = 0.008), and HER2-positive rate ( < 0.001). Compared with patients without mutations, those with mutations were more likely to have a family history of breast or ovarian cancer ( < 0.001) and have triple-negative breast cancer (TNBC) ( < 0.001). Family history of breast or ovarian cancer (odds ratio [OR], 103.58; 95% confidence interval [CI], 20.58-521.45; < 0.001) and TNBC subtype (OR, 5.97; 95% CI, 1.16-30.90; = 0.033) were independent predictors for mutation.
The clinicopathological characteristics of patients with breast cancer in this rural area have changed during the past decade. testing should be performed in patients with breast cancer with a family history of breast or ovarian cancer and TNBC.
尽管中国农村地区乳腺癌负担仍然特别高，但关于乳腺癌患者的临床病理特征及乳腺癌易感基因1/2（）突变患病率的数据仍然有限。我们调查了乳腺癌患者的临床病理特征、变化模式及突变患病率。
评估了2005年1月至2018年12月期间在梅州市人民医院接受治疗的3712例经病理确诊的原发性乳腺癌女性患者的临床病理特征。还评估了2017年1月至2018年9月期间确诊的340例乳腺癌患者的突变患病率。
诊断时的中位年龄为49±10.5（范围20 - 94）岁。分别有59.0%、52.5%和24.9%的患者雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（HER2）呈阳性。时间趋势分析显示，诊断年龄（ = 0.001）、无生育史患者比例（ < 0.001）、绝经后患者（ = 0.001）、浸润性病理癌症类型（ = 0.008）、ER阳性率（ < 0.001）、PR阳性率（ = 0.008）和HER2阳性率（ < 0.001）呈上升趋势。与无突变患者相比，有突变的患者更可能有乳腺癌或卵巢癌家族史（ < 0.001）且患三阴性乳腺癌（TNBC）（ < 0.001）。乳腺癌或卵巢癌家族史（比值比[OR]，103.58；95%置信区间[CI]，20.58 - 521.45； < 0.001）和TNBC亚型（OR，5.97；95% CI，1.16 - 30.90； = 0.033）是突变的独立预测因素。
在过去十年中，该农村地区乳腺癌患者的临床病理特征发生了变化。对于有乳腺癌或卵巢癌家族史以及TNBC的乳腺癌患者应进行检测。
